(Q50653774)

17 March 2018

title

Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. (English)

1 reference

17 March 2018

0 references

1 reference

4

1 reference

17 March 2018

author name string

I Qurashi

series ordinal

1

1 reference

17 March 2018

J D Collins

series ordinal

2

1 reference

17 March 2018

I B Chaudhry

series ordinal

3

1 reference

17 March 2018

language of work or name

English

0 references

publication date

19 March 2014

1 reference

17 March 2018

Journal of Psychopharmacology

published in

1 reference

17 March 2018

volume

28

1 reference

17 March 2018

issue

7

1 reference

17 March 2018

page(s)

707-708

1 reference

17 March 2018

Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

Minocycline: therapeutic potential in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

Minocycline as adjunctive therapy for schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

Clinical potential of minocycline for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114527358

21 January 2018

Identifiers

DOI

10.1177/0269881114527358

1 reference

17 March 2018

PubMed ID

24646811

1 reference

17 March 2018